Decheng Capital China Life Sciences USD Fund III, L.P. 4
4 · ALPINE IMMUNE SCIENCES, INC. · Filed Jan 22, 2024
Insider Transaction Report
Form 4
Transactions
- Exercise of In-Money
Common Stock
2024-01-18$12.74/sh+1,234,636$15,729,263→ 6,582,380 total - Exercise of In-Money
Warrant (right to buy)
2024-01-18−1,234,636→ 0 totalExercise: $12.74From: 2019-01-18Exp: 2024-01-18→ Common Stock (1,234,636 underlying)
Footnotes (1)
- [F1]The reportable securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Xiangmin Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. GP III disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Dr. Cui is a director of the Issuer and files separate Section 16 reports.